Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

— Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets — ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent BRead More